B.H.R. (Bruce) Wolffenbuttel

Field/Discipline

• Endocrinology & Metabolism

Expertise

Other positions

• Internist-endocrinologist, Professor emeritus
• Additional activities: 2004-2012 Scientific Director LifeLines Biobank & Cohort Study,
• Additional activities: Membership national / European KP6/7 & Horizon-2020 scientific collaborations BBMRI-NL, BioSHaRe-EU, NCHA, MDS-Right, BOTERO.. i.o. BOTERO-2; Secretary Dutch Society for Endocrinology (2009-2018)
• .
• Lid bestuur PREVEND studie
• Membership national / European KP6/7 & Horizon-2020 scientific collaborations BBMRI-NL, BioSHaRe-EU, NCHA, MDS-Right, BOTERO.. i.o. BOTERO-2
• .
• .
• Advisory Board Ascensia (2018); Member Editorial Board Journal of Diabetes; writing columns for Dutch Thyroid Patient Association SON (until 2020)
• Eur. GLP1 Adv. Board Novo Nordisk (2019); Principal Investigator SURE NL Semaglutide Post-Authorization study (https://pubmed.ncbi.nlm.nih.gov/36542260/)
• Scientific Advisor at Ancora Health (zie https://ancora.health/nl/over-ons/)
• Scientific Advisor / MD at Nuevo Care
• Active Member CluB12 UK
• Member Post-Graduate Education Committee EASD (until 1-1-2024)
• Coordinator / organiser for Post-Graduate Educations and Webinars, Diabetes (Alpha Omega Congress) & Endocrinology (BIG5 Endocrinology course) .
• Writing columns for magazine of the Dutch Pituitary Society HYPO Nieuws
• .